CTOs on the Move

Hexagon Bio

www.hexagonbio.com

 
Hexagon Bio is a data-driven biotech developing targeted small molecule therapeutics.
  • Number of Employees: 0-25
  • Annual Revenue: $0-1 Million

Executives

Name Title Contact Details

Funding

Hexagon Bio raised $47M on 09/15/2020

Similar Companies

Green Point Research

Working to cultivate a better tomorrow by bringing together human, natural & financial resources to grow our businesses and communities.

AAI Pharmaceutical

AAI Pharmaceutical is a Wilmington, NC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

HistoWiz

HistoWiz is an innovative company dedicated to accelerating pathology-based research. HistoWiz provides fast, global access to digital whole-slide images, online collaboration tools, low-cost data management, and experimental pathology expertise. The web-based platform accelerates information exchange among medical scientists and research pathologists. HistoWiz`s mission is to fight cancer cooperatively instead of individually by connecting scientists and pathologists for online collaboration.

Novome Biotechnologies

Novome Biotechnologies is engineering bacteria from the human gut to treat diseases. Based on pioneering technology developed at Stanford University, we bring together experts in the fields of synthetic biology and the microbiome to build novel cell-based therapies.

Progenics

Progenics Pharmaceuticals, Inc. is developing innovative medicines for oncology, with a pipeline that includes several product candidates in later-stage clinical development. Progenics` first-in-class PSMA-targeted technology platform for prostate cancer includes an antibody drug conjugate therapeutic which completed a two-cohort phase 2 clinical trial and a small molecule imaging agent that has also completed a phase 2 trial. Among other assets in its pipeline of targeted radiotherapy and molecular imaging compounds is Azedra™, an ultra-orphan radiotherapy candidate currently in a phase 2 study under an SPA. Progenics’ first commercial product, RELISTOR® (methylnaltrexone bromide) for opioid-induced constipation, is partnered with and marketed by Salix Pharmaceuticals, Ltd., a Valeant Pharmaceuticals International, Inc.